Parmax Pharma Ltd - 540359 - Closure of Trading Window
Closure of trading window31-03-2022
Parmax Pharma Ltd - 540359 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Submission of Advertisement Clipping of Extract of the Unaudited Financial Results for the quarter and nine months ended 31st December, 202116-02-2022
Parmax Pharma Ltd - 540359 - Board Meeting Outcome for Outcome Of The Meeting Of The Board Of Directors Of The Company
Board of Directors of the Company has, at its meeting held today, inter-alia, considered and approved: Unaudited Financial Results for quarter and nine months ended 31st December, 202114-02-2022
Parmax Pharma Ltd - 540359 - Board Meeting Intimation for Intimation Of Board Meeting In Compliance With Reg. 29 Read With Reg. 33 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.
Parmax Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2022 ,inter alia, to consider and approve Intimation of Board Meeting in compliance with Reg. 29 read with Reg. 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.07-02-2022
Parmax Pharma Ltd - 540359 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended 31st December, 2021.21-01-2022
Parmax Pharma Ltd - 540359 - Shareholding for the Period Ended December 31, 2021
Parmax Pharma Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2021. For more details, kindly Click here12-01-2022
Parmax Pharma Ltd - 540359 - Statement Of Investor Complaints For The Quarter Ended December 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- YASH VORADesignation :- Company Secretary and Compliance Officer03-01-2022
Parmax Pharma Ltd - 540359 - Disclosures under Reg. 10(7) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 10(7) in respect of acquisition under Regulation 10(1)(a)(i)of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Vipul M Gopani15-12-2021
Parmax Pharma Ltd - 540359 - Clarification On Price Movement
Clarification on price movement14-12-2021